Copyright
©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 28, 2017; 23(20): 3713-3720
Published online May 28, 2017. doi: 10.3748/wjg.v23.i20.3713
Published online May 28, 2017. doi: 10.3748/wjg.v23.i20.3713
Study on the value of serum miR-106b for the early diagnosis of hepatocellular carcinoma
Bao-Min Shi, Kun Ji, Yu-Feng Wang, Shuai Xiao, Department of General Surgery, Tongji Hospital, Medical School of Tongji University, Shanghai 200065, China
Wen Lu, Xiu-Yan Wang, Department of Ultrasound, Tongji Hospital, Medical School of Tongji University, Shanghai 200065, China
Author contributions: Shi BM, Lu W and Wang XY performed the majority of experiments; Shi BM, Lu W, Ji K, Wang YF, Xiao S and Wang XY provided vital reagents and analytical tools and were also involved in editing the manuscript; Wang XY co-ordinated and provided the collection of all the human material in addition to providing financial support for this work; Shi BM, Lu W and Wang XY designed the study and wrote the manuscript; Shi BM and Lu W contributed equally to this study.
Institutional review board statement: The study was reviewed and approved by the Tongji Hospital Affiliated to Tongji University Institutional Review Board.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: No potential conflicts of interest relevant to this article were reported.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Xiu-Yan Wang, Chief Physician, Department of Ultrasound, Tongji Hospital, Medical School of Tongji University, No 389 Xincun Road, Shanghai 200065, China. tjwangxiuyan@163.com
Telephone: +86-10-66111137 Fax: +86-10-66111137
Received: January 21, 2017
Peer-review started: January 22, 2017
First decision: February 21, 2017
Revised: March 7, 2017
Accepted: March 21, 2017
Article in press: March 21, 2017
Published online: May 28, 2017
Peer-review started: January 22, 2017
First decision: February 21, 2017
Revised: March 7, 2017
Accepted: March 21, 2017
Article in press: March 21, 2017
Published online: May 28, 2017
Core Tip
Core tip: Primary hepatocellular carcinoma (HCC) is the cause of a large number of patient deaths each year, and presents a heavy financial burden to the community and family. MicroRNAs (miRNAs) have been proven to be involved in the development of various cancers, as well as during the development process. Among these miRNAs, miR-106b has been shown to be a potential diagnostic marker for early HCC. We randomly selected the sera of medical examiners and detected their miR-106b level and further verified the diagnostic value of miR-106b, and provided more data to support the clinical application of miR-106b in evidence-based medicine.